Paul Averback
Fortuna: 4 M $ al 30/06/2025
Fortuna: 4 M $ al 30/06/2025
Paul Averback is the founder of Nymox Pharmaceutical Corp.
since 1995, holding the title of Co-Chairman, President & Chief Executive Officer.
Former job includes President at DMS Pharmaceutical Group, Inc. Education includes a doctorate from the University of Cambridge, conferred in 1975.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NYMOX PHARMACEUTICAL CORP 37,43 % | 19/04/2025 | 35.008.010 ( 37,43 % ) | 4 M $ | 30/06/2025 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NYMOX PHARMACEUTICAL CORPORATION | Director Ejecutivo | 30/09/1995 |
| Empresas | Cargo | Fin |
|---|---|---|
DMS Pharmaceutical Group, Inc.
DMS Pharmaceutical Group, Inc. Medical DistributorsDistribution Services Supplies pharmaceutical products | Presidente | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Nymox Pharmaceutical Corp.
Nymox Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which specializes in the research and development of products for the aging population | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DMS Pharmaceutical Group, Inc.
DMS Pharmaceutical Group, Inc. Medical DistributorsDistribution Services Supplies pharmaceutical products | Distribution Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.